Associated Papers
miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson's disease.
Suvarna V et al.
Frontiers in Pharmacology, 2022
Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect?
Redenšek S et al.
Frontiers in Aging Neuroscience, 2017
Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.
Wales P et al.
Journal of Parkinson's Disease, 2013
Select a paper to view details